🕵️ Entrada Therapeutics, Inc. ($TRDA)
SEC insider & ownership activity, last 12 months · CIK 1689375 · every row links its SEC filing
Over the last 12 months insiders sold $15.1M against $1.6M of open-market buying. Parmar Kush sold $3.6M (Nov–Aug). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
2 buyers, $1.6M (17 lots) · 7 sellers, $15.1M (44 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Parmar Kush | 0 | – | 6 | $3.6M | Aug 10, 2026 |
| MPM Bioventures 2014, L.P. | 0 | – | 12 | $3.6M | Sep 9, 2026 |
| MPM Bioventures 2018, L.P. | 0 | – | 12 | $3.6M | Sep 9, 2026 |
| 5AM Ventures V, L.P. | 0 | – | 5 | $3.0M | Aug 7, 2026 |
| Baker BROS. Advisors LP | 16 | $1.6M | 0 | – | Nov 20, 2025 |
| Kory Wentworth | 0 | – | 5 | $434K | Apr 1, 2026 |
| Nathan Dowden | 0 | – | 3 | $426K | May 4, 2026 |
| Natarajan Sethuraman | 0 | – | 1 | $399K | May 4, 2026 |
| Bernhardt G. Zeiher | 1 | $29K | 0 | – | May 20, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Kush Parmar | 10.8% | 13D | Nov 14, 2025 | filing ↗ | |
| Andrew J. Schwab | 10.6% | 13D | Nov 14, 2025 | filing ↗ | |
| Luke Evnin | 9.9% | 13D | Sep 8, 2026 | filing ↗ | |
| Ansbert Gadicke | 9.9% | 13D | Sep 8, 2026 | filing ↗ | |
| Todd Foley | 9.9% | 13D | Sep 8, 2026 | filing ↗ | |
| 5AM Ventures V, L.P. | 7.8% | 13D | Nov 14, 2025 | filing ↗ | |
| 5AM Partners V, LLC | 7.8% | 13D | Nov 14, 2025 | filing ↗ | |
| Scott M. Rocklage | 7.8% | 13D | Nov 14, 2025 | filing ↗ | |
| Roche Finance Ltd | 6.9% | 13G | Feb 14, 2025 | filing ↗ | |
| Roche Holding Ltd | 6.9% | 13G | Feb 14, 2025 | filing ↗ | |
| BlackRock, Inc. | 5.3% | 13G | Feb 4, 2025 | filing ↗ | |
| Janus Henderson Biotech Innovation Master Fund Ltd | 5.0% | 13G | May 14, 2025 | filing ↗ | |
| MPM BioVentures 2014 LLC | 5.0% | 13D | Sep 8, 2026 | filing ↗ | |
| MPM BioVentures 2018 LLC | 5.0% | 13D | Sep 8, 2026 | filing ↗ | |
| MPM BioVentures 2018 GP LLC | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM BioVentures 2014 GP LLC | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM Bioventures 2018, L.P. | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM BioVentures 2014, L.P. | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM BioVentures 2014 (B), L.P. | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM Asset Management Investors BV2014 LLC | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM Bioventures 2018 (B), L.P. | exited | 13D | Sep 8, 2026 | filing ↗ | |
| MPM Asset Management Investors BV2018 LLC | exited | 13D | Sep 8, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| 5AM Ventures V, L.P. | $1.1M | Jul 30, 2026 | filing ↗ |
| 5AM Ventures V, L.P. | $1.1M | Jul 30, 2026 | filing ↗ |
| Nathan Dowden | $218K | May 4, 2026 | filing ↗ |
| Natarajan Sethuraman | $376K | May 4, 2026 | filing ↗ |
| Kory Wentworth | $32K | Apr 1, 2026 | filing ↗ |
| Kory Wentworth | $207K | Mar 9, 2026 | filing ↗ |
| Nathan Dowden | $189K | Mar 9, 2026 | filing ↗ |
| Kory Wentworth | $95K | Mar 4, 2026 | filing ↗ |
| Kory Wentworth | $82K | Nov 21, 2025 | filing ↗ |
| 5AM Ventures V, L.P. | $1.8M | Nov 14, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | Aug 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 5, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 10, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 10, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 18, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Earnings (2.02) | Feb 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 26, 2026 | filing ↗ |
| Earnings (2.02) | Jan 8, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 8, 2026 | filing ↗ |
| Other events (8.01) | Jan 8, 2026 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |